This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 1990 Jun 9;335(8702):1403.

doi: 10.1016/0140-6736(90)91282-f.

Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate

C M Kessler, K Sachse

PMID: 1971683
DOI: 10.1016/0140-6736(90)91282-f

Case Reports

Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate

C M Kessler et al. Lancet. 1990.

. 1990 Jun 9;335(8702):1403.

doi: 10.1016/0140-6736(90)91282-f.

Authors

C M Kessler, K Sachse

PMID: 1971683
DOI: 10.1016/0140-6736(90)91282-f

No abstract available

PubMed Disclaimer

Comment in

Factor VIII:C inhibitor associated with monoclonal-antibody-purified FVIII concentrate.
Rodell MB, Bergman GE. Rodell MB, et al. Lancet. 1990 Aug 11;336(8711):373. doi: 10.1016/0140-6736(90)91912-t. Lancet. 1990. PMID: 1975350 No abstract available.
Lack of inhibitor to monoclonal-antibody purified FVIII concentrate.
Mondorf W, Scharrer I. Mondorf W, et al. Lancet. 1990 Sep 22;336(8717):747. doi: 10.1016/0140-6736(90)92240-i. Lancet. 1990. PMID: 1975915 No abstract available.

Similar articles

Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Baglin T, Beacham E. Baglin T, et al. Thromb Haemost. 1998 Dec;80(6):1036-7. Thromb Haemost. 1998. PMID: 9869186 No abstract available.
Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.
Kruse-Jarres R. Kruse-Jarres R. Hematology Am Soc Hematol Educ Program. 2011;2011:407-12. doi: 10.1182/asheducation-2011.1.407. Hematology Am Soc Hematol Educ Program. 2011. PMID: 22160066 Review.
[Natural history of anti-factor VIII antibodies in hemophilia A patients].
Allain JP. Allain JP. Rev Fr Transfus Immunohematol. 1985 Dec;28(6):581-9. doi: 10.1016/s0338-4535(85)80003-9. Rev Fr Transfus Immunohematol. 1985. PMID: 3938057 Review. French. No abstract available.
Complications of hemophilia A treatment: factor VIII inhibitors.
Kasper CK. Kasper CK. Ann N Y Acad Sci. 1991;614:97-105. doi: 10.1111/j.1749-6632.1991.tb43695.x. Ann N Y Acad Sci. 1991. PMID: 1902643 Review. No abstract available.
Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K, Schwarz P, Kunschak M. Schimpf K, et al. Thromb Haemost. 1995 Mar;73(3):553-5. Thromb Haemost. 1995. PMID: 7667845 No abstract available.

See all similar articles

Cited by

High potency factor VIII concentrates: value not proved?
Cash JD. Cash JD. BMJ. 1991 Sep 14;303(6803):633-4. doi: 10.1136/bmj.303.6803.633. BMJ. 1991. PMID: 1932909 Free PMC article. No abstract available.
High potency factor VIII concentrates.
Mayne EE. Mayne EE. BMJ. 1992 Feb 1;304(6822):319. doi: 10.1136/bmj.304.6822.319-b. BMJ. 1992. PMID: 1739845 Free PMC article. No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information